Radiosurgery systems maker
) announced that more than half a million cancer patients across
the globe have been treated with its flagship CyberKnife and
TomoTherapy systems. To date, more than 700 systems have been
sold by the company across 40 countries.
ANGIODYNAMICS (ANGO): Free Stock Analysis
ACCURAY INC (ARAY): Free Stock Analysis
NATUS MEDICAL (BABY): Free Stock Analysis
CRYOLIFE INC (CRY): Free Stock Analysis
To read this article on Zacks.com click here.
This news failed to boost ARAY's shares immediately as the
company had already announced that in its last reported quarter
it has installed a total of 706 units. However, we note that
shares of this company have risen 19.1% ever since it reported
its first-quarter fiscal 2014 results on Nov 7.
Management asserts that widespread adoption of Accuray's latest
offerings is an indication of the company's ability to grow in
the long run. Two of the new products which are garnering healthy
attraction in the global oncology community are the CyberKnife M6
Series and the TomoTherapy H Series.
Currently, Accuray has a Zacks Rank #4 (Sell). The company's
first-quarter fiscal 2014 loss of 21 cents per share was wider
than the Zacks Consensus Estimate of a loss of 19 cents per
share. Revenues of this radiosurgery systems maker dropped 7% to
$76.6 million due to continued fall in product sales. The top
line also missed the Zacks Consensus Estimate of $83 million.
Despite the revenue miss, a 17% year-over-year growth in gross
orders to $63.4 million was the highlight of the quarter. Accuray
added net new system orders worth $60.1 million, leading to a
total system backlog of $347.8 million, up 18% year over year.
The company shipped 13 and installed 14 new CyberKnife and
TomoTherapy systems during the quarter.
Moreover, on an encouraging note, the California-based company
reiterated its revenue outlook for fiscal 2014. Revenues are
expected in the range of $325 to $345 million for the fiscal
While we choose to avoid Accuray at present, some better-ranked
stocks in the medical instruments sector include
Natus Medical Inc.
). While Natus carries a Zacks Rank #1 (Strong Buy),
AngioDynamics and CryoLife hold a Zacks Rank #2 (Buy).